Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MLSS
MLSS logo

MLSS Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.300
Open
0.295
VWAP
0.29
Vol
197.51K
Mkt Cap
22.65M
Low
0.283
Amount
57.38K
EV/EBITDA(TTM)
--
Total Shares
78.63M
EV
22.39M
EV/OCF(TTM)
--
P/S(TTM)
2.64
Milestone Scientific Inc. is a biomedical technology company. The Company patents, designs, develops and commercializes diagnostic and therapeutic injection technologies and devices for medical and dental use. The Company operates through two segments: dental and medical. The Company has developed a computer-controlled anesthetic delivery device, its DPS Dynamic Pressure Sensing Technology System, to meet the needs of various subcutaneous drug delivery injections and fluid aspiration. Its device, using The Wand, a single-use disposable handpiece, is marketed in dentistry under the trademarks CompuDent and STA Single Tooth Anesthesia System, and is suitable for all dental procedures that require local anesthetic. The dental devices are sold in the United States, Canada and in over 41 other countries. In addition, the Company has obtained CE mark approval for certain medical devices, which can be marketed and sold in various European countries.
Show More

Events Timeline

(ET)
2026-03-31
16:40:00
Milestone Scientific CEO Emphasizes Financial Discipline
select
2026-03-31
16:40:00
Company Plans to Achieve Cash Flow Breakeven by 2027
select
2026-02-23 (ET)
2026-02-23
08:40:00
Milestone Scientific Launches CompuFlo Advisor Program
select
2026-01-06 (ET)
2026-01-06
08:40:00
Milestone Scientific Launches The Wand Ambassador Program
select
2025-10-14 (ET)
2025-10-14
07:52:23
Milestone Scientific Showcases Growth Strategies Under New CEO Eric Hines
select
2025-10-14
07:49:11
Milestone Scientific Gets Non-Compliance Notice from NYSE American
select
2025-09-22 (ET)
2025-09-22
09:22:52
Milestone Scientific names Dawood Sayed to its board of directors
select
2025-08-06 (ET)
2025-08-06
08:34:44
Milestone Scientific appoints Jason Papes SVP, global head of sales, marketing
select
2025-08-01 (ET)
2025-08-01
08:33:49
Milestone Scientific appoints Hines as CEO
select

News

seekingalpha
9.5
04-01seekingalpha
PinnedMilestone Scientific Releases 2026 Outlook with Revenue Growth Expectations
  • Earnings Report: Milestone Scientific reported a FY GAAP EPS of -$0.07, aligning with expectations, while revenue of $8.97 million, a 3.9% year-over-year increase, fell short of the $9.00 million consensus, indicating challenges in revenue growth.
  • 2026 Outlook: Management anticipates total revenue for 2026 to range between $9.8 million and $10.2 million, although below the consensus of $9.91 million, reflecting expected double-digit growth driven by broader commercial adoption in both dental and medical sectors.
  • CompuFlo Revenue Forecast: For 2026, CompuFlo revenue is projected to be between $500,000 and $600,000, representing an approximate 400% increase over 2025, highlighting strong growth potential in specific product lines that may attract investor interest.
  • Cost Structure Optimization: Coupled with structural cost reductions implemented in 2025, the anticipated revenue growth in 2026 is expected to yield improved operating leverage and a significant reduction in cash burn compared to the previous year, enhancing the company's financial health.
Yahoo Finance
9.5
04-01Yahoo Finance
Milestone Scientific Reports Q4 2025 Earnings and Future Guidance
  • Revenue Growth: Q4 2025 revenue reached $2.1 million, a 2.2% increase from $2 million in Q4 2024, indicating stability in the market despite modest growth, which may present future opportunities.
  • Improved Operating Loss: The operating loss for Q4 2025 was $1.1 million, an 89% improvement from $2 million in Q4 2024, demonstrating significant progress in cost control and operational efficiency.
  • Future Guidance: The 2026 revenue guidance is set between $9.8 million and $10.2 million, reflecting expectations of double-digit year-over-year growth, showcasing the company's confidence in future market demand and strategic positioning.
  • International Market Expansion: Milestone Scientific's dental business is gaining traction in countries like Japan, India, and Mexico, indicating the company's proactive approach to seeking growth opportunities in international markets to enhance its global competitiveness.
seekingalpha
9.5
04-01seekingalpha
Milestone Scientific Q4 2025 Earnings Call Insights
  • Management Restructuring: CEO Eric Hines, who took over in August 2025, immediately scrutinized company expenditures, cutting non-revenue-generating costs to ensure effective resource utilization, thereby laying a foundation for future growth.
  • Revenue Growth Outlook: Management projects total revenue for 2026 to be between $9.8 million and $10.2 million, reflecting double-digit year-over-year growth primarily driven by continued adoption in international markets and dental products, indicating the company's market potential.
  • CompuFlo Initiative: Hines emphasized that the CompuFlo system will be a key growth driver, with expected contributions of $500,000 to $600,000 in 2026, representing approximately a 400% increase over 2025, which will significantly enhance the company's competitive position in the market.
  • Cash Flow Target: Management has set a goal to achieve cash flow breakeven by early 2027, and combined with cost control measures from 2025, this is expected to significantly improve operating leverage and reduce cash burn, enhancing the company's financial stability.
Newsfilter
8.5
02-23Newsfilter
Milestone Scientific Launches CompuFlo Advisor Program to Boost Adoption
  • Strategic Initiative Launched: Milestone Scientific launched the CompuFlo® Advisor Program on February 1, 2026, aimed at driving mainstream commercial adoption and increasing recurring disposable revenue to optimize long-term Medicare reimbursement rates.
  • Target Market Defined: The program focuses on high-volume interventional pain and anesthesia practices within key Medicare Administrative Contractor jurisdictions, including Novitas, First Coast, Noridian, and Palmetto, marking the first phase of strategic execution across the U.S.
  • Clinical Data Generation: By collaborating with Key Opinion Leaders, Milestone aims to generate 1,000 to 2,000 case submissions in the initial six months to transition CPT® code 0777T from Category III to Category I, which is expected to enhance commercial adoption and long-term revenue visibility.
  • Robust Support Infrastructure: The company has deployed a strong commercial infrastructure and engaged industry veterans to provide real-time claims support and documentation guidance, ensuring the Advisor Program can deliver a scalable recurring revenue model to facilitate nationwide expansion.
Benzinga
5.0
2025-12-31Benzinga
Vanda Pharmaceuticals' NEREUS Receives FDA Approval, Shares Surge 17.5%
  • FDA Approval: Vanda Pharmaceuticals' NEREUS (tradipitant) has received FDA approval for the prevention of motion-induced vomiting in adults, marking a significant advancement in the company's neuropharmaceutical portfolio and is expected to drive future sales growth.
  • Stock Surge: Following the FDA approval announcement, Vanda's shares jumped 17.5% to $8.26 in pre-market trading, reflecting strong market confidence in the new drug's potential and likely attracting increased investor interest.
  • Market Outlook: The approval of NEREUS not only opens new market opportunities for Vanda Pharmaceuticals but also enhances its market share in the competitive antiemetic drug sector, strengthening the company's long-term profitability prospects.
  • Investor Confidence: This FDA approval boosts investor expectations for Vanda's future performance, potentially prompting more institutional investors to reassess their portfolios, further driving the stock price upward.
Benzinga
4.0
2025-11-20Benzinga
Benchmark Keeps Speculative Buy Rating on Milestone Scientific, Reduces Price Target to $1
  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from shared intelligence.

  • Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.

Wall Street analysts forecast MLSS stock price to rise
2 Analyst Rating
Wall Street analysts forecast MLSS stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
1.00
Averages
1.00
High
1.00
Current: 0.000
sliders
Low
1.00
Averages
1.00
High
1.00
Benchmark
Speculative Buy
downgrade
$1
AI Analysis
2025-11-20
Reason
Benchmark
Price Target
$1
AI Analysis
2025-11-20
downgrade
Speculative Buy
Reason
Benchmark lowered the firm's price target on Milestone Scientific to $1 from $1.25 and keeps a Speculative Buy rating on the shares. Sales traction for the Medical business has proven to be elusive, so the firm is lowering its forward revenue estimates, noting that its 2030 revenue estimate of $22M is discounted to the end of 2026 at 8.2% to arrive at its lowered price target.

Valuation Metrics

The current forward P/E ratio for Milestone Scientific Inc (MLSS.A) is 18.22, compared to its 5-year average forward P/E of -13.36. For a more detailed relative valuation and DCF analysis to assess Milestone Scientific Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-13.36
Current PE
18.22
Overvalued PE
-3.84
Undervalued PE
-22.88

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.21
Current EV/EBITDA
-4.51
Overvalued EV/EBITDA
0.73
Undervalued EV/EBITDA
-1.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
6.96
Current PS
2.29
Overvalued PS
10.65
Undervalued PS
3.27

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what socks to buy today with 5% return
Intellectia · 244 candidates
Region: USList Exchange: XNYS, XNAS, XASEOne Week Predict Return: >= 5.0%
Ticker
Name
Market Cap$
top bottom
PRLB logo
PRLB
Proto Labs Inc
1.59B
ATEC logo
ATEC
Alphatec Holdings Inc
2.05B
LYRA logo
LYRA
Lyra Therapeutics Inc
3.23M
BHB logo
BHB
Bar Harbor Bankshares
594.59M
TROW logo
TROW
T Rowe Price Group Inc
20.68B
CRM logo
CRM
Salesforce Inc
179.29B
stock under 5$ bulish for tomorrow
Intellectia · 447 candidates
Price: <= $5.00
Ticker
Name
Market Cap$
top bottom
SXTC logo
SXTC
China SXT Pharmaceuticals Inc
11.70M
ZJYL logo
ZJYL
Jin Medical International Ltd
19.82M
WCT logo
WCT
Wellchange Holdings Co Ltd
22.89M
PASW logo
PASW
Ping An Biomedical Co Ltd
3.72M
JOB logo
JOB
GEE Group Inc
23.64M
UGRO logo
UGRO
urban-gro Inc
3.53M
200 usd to start now wats my first step
Intellectia · 3944 candidates
Region: USPrice: $0.00 - $200.00
Ticker
Name
Market Cap$
top bottom
SXTC logo
SXTC
China SXT Pharmaceuticals Inc
11.70M
APLT logo
APLT
Applied Therapeutics Inc
14.63M
ZJYL logo
ZJYL
Jin Medical International Ltd
19.82M
CENN logo
CENN
Cenntro Inc (The Corporation)
12.95M
BURU logo
BURU
NUBURU Inc
77.15M
WORX logo
WORX
Scworx Corp
2.85M

Whales Holding MLSS

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Milestone Scientific Inc (MLSS) stock price today?

The current price of MLSS is 0.288 USD — it has decreased -5.26

What is Milestone Scientific Inc (MLSS)'s business?

Milestone Scientific Inc. is a biomedical technology company. The Company patents, designs, develops and commercializes diagnostic and therapeutic injection technologies and devices for medical and dental use. The Company operates through two segments: dental and medical. The Company has developed a computer-controlled anesthetic delivery device, its DPS Dynamic Pressure Sensing Technology System, to meet the needs of various subcutaneous drug delivery injections and fluid aspiration. Its device, using The Wand, a single-use disposable handpiece, is marketed in dentistry under the trademarks CompuDent and STA Single Tooth Anesthesia System, and is suitable for all dental procedures that require local anesthetic. The dental devices are sold in the United States, Canada and in over 41 other countries. In addition, the Company has obtained CE mark approval for certain medical devices, which can be marketed and sold in various European countries.

What is the price predicton of MLSS Stock?

Wall Street analysts forecast MLSS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLSS is1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Milestone Scientific Inc (MLSS)'s revenue for the last quarter?

Milestone Scientific Inc revenue for the last quarter amounts to 2.06M USD, increased 2.21

What is Milestone Scientific Inc (MLSS)'s earnings per share (EPS) for the last quarter?

Milestone Scientific Inc. EPS for the last quarter amounts to -0.01 USD, decreased -66.67

How many employees does Milestone Scientific Inc (MLSS). have?

Milestone Scientific Inc (MLSS) has 17 emplpoyees as of April 02 2026.

What is Milestone Scientific Inc (MLSS) market cap?

Today MLSS has the market capitalization of 22.65M USD.